141 related articles for article (PubMed ID: 31598748)
41. eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.
Ulivi P; Scarpi E; Passardi A; Marisi G; Calistri D; Zoli W; Del Re M; Frassineti GL; Tassinari D; Tamberi S; Vertogen B; Amadori D
J Transl Med; 2015 Aug; 13():258. PubMed ID: 26259598
[TBL] [Abstract][Full Text] [Related]
42. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
[TBL] [Abstract][Full Text] [Related]
43. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.
Cortejoso L; García MI; García-Alfonso P; González-Haba E; Escolar F; Sanjurjo M; López-Fernández LA
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1463-72. PubMed ID: 23543295
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
[TBL] [Abstract][Full Text] [Related]
45. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
To KK; Leung WW; Ng SS
Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
[TBL] [Abstract][Full Text] [Related]
46. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.
Mlcochova J; Faltejskova-Vychytilova P; Ferracin M; Zagatti B; Radova L; Svoboda M; Nemecek R; John S; Kiss I; Vyzula R; Negrini M; Slaby O
Oncotarget; 2015 Nov; 6(36):38695-704. PubMed ID: 26497852
[TBL] [Abstract][Full Text] [Related]
47. Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
Akiyama Y; Fujita K; Ishida H; Sunakawa Y; Yamashita K; Kawara K; Miwa K; Saji S; Sasaki Y
Drug Metab Pharmacokinet; 2012; 27(3):325-35. PubMed ID: 22201120
[TBL] [Abstract][Full Text] [Related]
48. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
[TBL] [Abstract][Full Text] [Related]
49. Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in
Townsend A; Tebbutt N; Karapetis C; Cooper P; Singhal N; Yeend S; Pirc L; Joshi R; Hardingham J; Price T
Clin Cancer Res; 2018 Aug; 24(16):3838-3844. PubMed ID: 29739790
[No Abstract] [Full Text] [Related]
50. Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer.
Dong N; Meng F; Wu Y; Wang M; Cui Y; Zhang S
Tumour Biol; 2015 Sep; 36(10):7691-8. PubMed ID: 25934339
[TBL] [Abstract][Full Text] [Related]
51. Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.
Yu QQ; Qiu H; Zhang MS; Hu GY; Liu B; Huang L; Liao X; Li QX; Li ZH; Yuan XL
World J Gastroenterol; 2016 Apr; 22(16):4250-8. PubMed ID: 27122675
[TBL] [Abstract][Full Text] [Related]
52. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
Berger MD; Stintzing S; Heinemann V; Cao S; Yang D; Sunakawa Y; Matsusaka S; Ning Y; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Zhang W; Cremolini C; Falcone A; Loupakis F; Lenz HJ
Clin Cancer Res; 2018 Feb; 24(4):784-793. PubMed ID: 29208668
[No Abstract] [Full Text] [Related]
53. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
54. Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine.
Paulík A; Nekvindová J; Filip S
Tumori; 2020 Apr; 106(2):87-94. PubMed ID: 30514181
[TBL] [Abstract][Full Text] [Related]
55. Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.
Labriet A; Lévesque É; Cecchin E; De Mattia E; Villeneuve L; Rouleau M; Jonker D; Couture F; Simonyan D; Allain EP; Buonadonna A; D'Andrea M; Toffoli G; Guillemette C
Sci Rep; 2019 Sep; 9(1):13008. PubMed ID: 31506518
[TBL] [Abstract][Full Text] [Related]
56. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
[TBL] [Abstract][Full Text] [Related]
57. UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
Liu X; Xu W
Pharmacogenomics; 2014 Jun; 15(9):1171-4. PubMed ID: 25141892
[No Abstract] [Full Text] [Related]
58. High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis at the time of initial diagnosis.
Rapti SM; Kontos CK; Papadopoulos IN; Scorilas A
Tumour Biol; 2016 Sep; 37(9):11815-11824. PubMed ID: 27044381
[TBL] [Abstract][Full Text] [Related]
59. Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Stenholm L; Stoehlmacher-Williams J; Al-Batran SE; Heussen N; Akin S; Pauligk C; Lehmann S; Senff T; Hofheinz RD; Ehninger G; Kramer M; Goekkurt E
Ann Oncol; 2013 Oct; 24(10):2581-2588. PubMed ID: 23975664
[TBL] [Abstract][Full Text] [Related]
60. Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study.
Michael M; Liauw W; McLachlan SA; Link E; Matera A; Thompson M; Jefford M; Hicks RJ; Cullinane C; Hatzimihalis A; Campbell IG; Rowley S; Beale PJ; Karapetis CS; Price T; Burge ME
Cancer Chemother Pharmacol; 2021 Jul; 88(1):39-52. PubMed ID: 33755789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]